Leadgene Biomedical

Latest News

Successful Registration of Key Products in US FDA DMF

We are excited to announce that Leadgene has successfully registered several key products with the US FDA Drug Master File (DMF).

Leadgene Biomedical Completes 100% Acquisition of SIDSCO to Drive Business Integration and Maximize Synergy

Leadgene Biomedical has successfully acquired 100% equity in SIDSCO. This strategic move is designed to integrate the operations of both companies, enhance synergies, and accelerate innovation and growth within the biotechnology sector.

Leadgene Indoxyl Sulfate (IS) ELISA Kit Awarded the 2024 Symbol of National Quality (SNQ)

This kit has been approved by the Taiwan Food and Drug Administration (TFDA) as a Class III in vitro diagnostic device (MOHW-MD-No. 007625). As the first patented product of its kind globally, it aims to provide new clinical detection solutions. This innovation is expected to enhance the prevention and management of kidney disease worldwide, reduce healthcare costs, and improve social welfare.

1

/

3

Leadgene Biomedical at the 2024 Healthcare+ Expo Taiwan!

Meet us at MEDICA Düsseldorf 2024!

Meet Us at MEDICAL FAIR ASIA 2024!

Leadgene Biomedical Expands in Northern Taiwan with New Innovation & Research Center and CLD Center

New Distributor Announcement - BioCell Corporation

Leadgene Biomedical, CYTENA BPS, and CYTENA Forge Tripartite Collaboration to Establish Cell Line Development Platform

Innovative Patented In Vitro Diagnostics Receives Market Approval

World Premiere: Leadgene Biomedical's Indoxyl Sulfate (IS) ELISA Kit Secures TFDA Approval

Leadgene Biomedical Embraces Openness and Strategic Partnerships for Global Market Expansion

Nanobody Development: Pioneering Tiny Titans for Next-Generation Biotechnology

Leadgene Biomedical Achieves Recognition as a Domestic CRO Service Company!

Leadgene Biomedical CEO Honored with 2023 Best Bio CEO Second Prize & Best Potential Prize

1
2
3